Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cellectis S.A. (CLLS : NSDQ)

• Company Description    Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France. Number of Employees: 294

• Price / Volume Information    Yesterday's Closing Price: $3.78 Daily Weekly Monthly 20 Day Moving Average: 164,287 shares Shares Outstanding: 45.49 (millions) Market Capitalization: $171.96 (millions) Beta: 2.24 52 Week High: $16.67 52 Week Low: $2.85 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.03% 6.96% 12 Week -11.89% -3.14% Year To Date -53.45% -40.86%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 8 RUE DE LA CROIX JARRY - PARIS,I0 75013 FRA ph: 33-1-81-69-16-00 fax: 33-1-81-69-16-06 investors@cellectis.com http://www.cellectis.com

• General Corporate Information    Officers Andre Choulika - Chief Executive Officer Jean-Pierre Garnier - Chairman of the Board Bing Wang - Chief Financial Officer David Sourdive - Executive Vice President Laurent Arthaud - Director Peer Information Cellectis S.A. (CORR.) Cellectis S.A. (RSPI) Cellectis S.A. (CGXP) Cellectis S.A. (BGEN) Cellectis S.A. (GTBP) Cellectis S.A. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 15117K103 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 45.49 Most Recent Split Date: (:1) Beta: 2.24 Market Capitalization: $171.96 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.58 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.19 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.85 Price/Cash Flow: - Price / Sales: 4.00 EPS Growth vs. Year Ago Period: -150.00% vs. Previous Quarter: -27.27% Sales Growth vs. Year Ago Period: -86.30% vs. Previous Quarter: -71.95% ROE 03/31/22 - -53.48 12/31/21 - -41.88 09/30/21 - -44.64 ROA 03/31/22 - -33.57 12/31/21 - -26.94 09/30/21 - -29.13 Current Ratio 03/31/22 - 3.73 12/31/21 - 4.57 09/30/21 - 4.75 Quick Ratio 03/31/22 - 3.73 12/31/21 - 4.57 09/30/21 - 4.72 Operating Margin 03/31/22 - -312.64 12/31/21 - -170.26 09/30/21 - -188.02 Net Margin 03/31/22 - -312.64 12/31/21 - -170.26 09/30/21 - -188.02 Pre-Tax Margin 03/31/22 - -336.58 12/31/21 - -186.53 09/30/21 - -205.18 Book Value 03/31/22 - 4.46 12/31/21 - 5.20 09/30/21 - 5.77 Inventory Turnover 03/31/22 - 22.79 12/31/21 - 13.26 09/30/21 - 17.04 Debt-to-Equity 03/31/22 - 0.09 12/31/21 - 0.08 09/30/21 - 0.09 Debt-to-Capital 03/31/22 - 8.29 12/31/21 - 7.81 09/30/21 - 7.99

Powered by Zacks Investment Research ©